Tumor Ablation Using AuroLase® Therapy
  • Particle-based thermal ablation of tumors
  • Initial human pilot study underway
  • Broadly applicable to most solid tumor types
  • Treats irregularly shaped tumors with precision
  • Preserves adjacent healthy tissue and structures
  • No evidence of particle toxicity

AuroLase Therapy is a novel medical device that is broadly applicable to many solid tumors. Nanospectra is currently conducting a pilot study in patients with refractory head and neck cancer under an open Investigational Device Exemption (IDE), and plans to commence additional clinical studies in other cancers in the near future.

AuroLase Therapy utilizes the unique "optical tunability" of a new class of nanoparticles that can convert light into heat to thermally destroy a solid tumor. These particles (AuroShell® particles, also referred to as nanoshells in scientific literature) are designed to absorb near-infrared wavelengths of light that can harmlessly penetrate human tissue. The particles are delivered intravenously and will accumulate in the tumor.  The tumor is then illuminated with a near-infrared laser. The particles will selectively absorb the laser energy, converting the light into heat which will thermally destroy the tumor and the blood vessels supplying it without significant damage to surrounding healthy tissue.

Because the particles do not accumulate in healthy tissue, and the laser energy does not destroy healthy tissue, AuroLase Therapy allows the precise thermal ablation of the tumor along its irregular boundaries while preserving the surrounding healthy tissue. AuroLase Therapy has demonstrated safety in animal studies with no evidence of systemic toxicity.